Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03962998 · ClinicalTrials.gov registry record · Early Phase 1
Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
A Early Phase 1 study of Crohn Disease, sponsored by MediBeacon.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03962998 is a Early Phase 1 study of Crohn Disease that has completed, run by MediBeacon. The registered enrollment target is 22 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03962998, a Early Phase 1 study of Crohn Disease, has completed, sponsored by MediBeacon.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).
Conditions Studied
Interventions
- DRUG Lactulose/Rhamnose solution
- DRUG MB-102
Study Locations (1)
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-10-27 |
| Est. Completion | 2021-10-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03962998
The ClinicalTrials.gov registry entry for NCT03962998 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (89% lower). The listed sponsor is MediBeacon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Lactulose/Rhamnose solution is the first listed.
NCT03962998 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03962998 about?
NCT03962998 is a clinical study titled "Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability". The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).
What is the current status of trial NCT03962998?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2019-10-27. Estimated completion is 2021-10-05.
What conditions does trial NCT03962998 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT03962998?
The interventions under investigation include: Lactulose/Rhamnose solution (DRUG), MB-102 (DRUG).
Who is sponsoring clinical trial NCT03962998?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03962998 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cranberry and Gut Health in Crohn's Disease
RECRUITING · Early Phase 1
-
Effect of Statins on Crohn's Disease
RECRUITING · Early Phase 1
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.